Group items matching

in title, tags, annotations or url

Thermo Fisher Scientific has partnered with molecular diagnostics company NX Prenatal to develop non-invasive tests for monitoring foetal health in the womb and assess the risk of adverse pregnancy outcomes.

The US Food and Drug Administration (FDA) has granted marketing clearance for Monarch, an external trigeminal nerve stimulation (eTNS) system developed by NeuroSigma, to treat attention deficit hyperactivity disorder (ADHD).

Inappropriate gastrointestinal (GI) testing has been reduced by almost half at a hospital in the Midwestern US through the implementation of an electronic diagnostic stewardship programme, saving thousands of dollars.

Boston Scientific has received the US Food and Drug Administration (FDA) approval for the use of LOTUS Edge Aortic Valve System to treat severe aortic stenosis.

Johnson & Johnson (J&J) subsidiary Ethicon has been ordered to pay $120m in damages by a Philadelphia court after it ruled that its negligently designed pelvic mesh implant caused a Pennsylvania woman to suffer from incontinence and chronic pain, Law360 has reported.

A team of researchers from Massachusetts Institute of Technology (MIT) and Massachusetts General Hospital (MGH) have created a new imaging system aid in the surgical removal of ovarian tumours.

University of Leeds researcher Alejandro Frangi has received funding support from the Royal Academy of Engineering to develop a new approach to discover, develop and test new medical devices based on computational 'in-silico' trials.

US-based medical technology firm iCAD is set to partner with two researchers at the Karolinska Institutet in Sweden on the development of an artificial intelligence (AI)-based system to detect individual risk of breast cancer development.

Late last year, research by the University of Chicago revealed that air pollution could be reducing global life expectancy rates by an average of 1.8 years per person. These figures would make air pollution the world's deadliest killer.

The US Food and Drug Administration (FDA) has highlighted concerns about using robotically assisted surgical devices for mastectomies and other cancer surgeries, citing a lack of evidence for safety and effectiveness.

Researchers at Harvard University in the US have designed a probe that looks, acts and feels like a real neuron so that the brain does not identify it as a foreign object and try to attack it.

Google has partnered with its sister company Verily to launch a screening programme that will leverage artificial intelligence (AI) to detect two eye diseases, diabetic retinopathy (DR) and diabetic macular oedema (DMO), in India.

German dialysis products and services company Fresenius Medical Care has completed the $2bn acquisition of US-based medical devices maker NxStage Medical, after receiving clearance from the US antitrust authorities.

Innovate UK, the country's innovation agency, has partnered with non-profit organisation Asthma UK to support three projects focused on the diagnosis and faster, personalised treatment of asthma.

23andMe has developed a test that could help predict the chances of an individual developing Type 2 diabetes based on their genetics, weight, age and lifestyle.

US Senators Pat Toomey and Amy Klobuchar have introduced bipartisan legislation to repeal medical device tax across the country.

A team at IBM Research Australia is developing a blood test to detect early stage Alzheimer's disease. Led by researcher Ben Goudey, the team used artificial intelligence (AI) technology to identify a set of proteins in blood that could predict amyloid-beta concentration in spinal fluid.

Paige.AI has received breakthrough device designation from the US Food and Drug Administration (FDA) for a cancer diagnosis solution based on artificial intelligence (AI).

Researchers at Indiana University School of Medicine in the US have discovered a blood test that could track stress intensity and help diagnose people suffering from post-traumatic stress disorder (PTSD).

Smith & Nephew has agreed to acquire regenerative medicine products developer Osiris Therapeutics for a total cash consideration of $660m.